<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="557">
  <stage>Registered</stage>
  <submitdate>11/04/2005</submitdate>
  <approvaldate>11/04/2005</approvaldate>
  <nctid>NCT00107965</nctid>
  <trial_identification>
    <studytitle>Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses</studytitle>
    <scientifictitle>A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 &amp; 2 or Day 1 &amp; 8 Applications to Actinic Keratoses</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2005/145</secondaryid>
    <secondaryid>PEP005-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Actinic Keratosis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEP005
Treatment: drugs - PEP005
Treatment: drugs - PEP005
Treatment: drugs - PEP005
Treatment: drugs - PEP005
Treatment: drugs - PEP005
Treatment: drugs - PEP005
Treatment: drugs - PEP005

Experimental: 1 - 

Experimental: 2 - 

Experimental: 3 - 

Placebo Comparator: 4 - 

Experimental: 5 - 

Experimental: 6 - 

Experimental: 7 - 

Placebo Comparator: 8 - 


Treatment: drugs: PEP005
0.0025% PEP005 Topical Gel (Day 1,2 application)

Treatment: drugs: PEP005
0.01% PEP005 Topical Gel (Day 1,2 application)

Treatment: drugs: PEP005
0.05% PEP005 Topical Gel (Day 1,2 application)

Treatment: drugs: PEP005
Vehicle Gel (Day 1,2 application)

Treatment: drugs: PEP005
0.0025% PEP005 Topical Gel (Day 1,8 application)

Treatment: drugs: PEP005
0.01% PEP005 Topical Gel (Day 1,8 application)

Treatment: drugs: PEP005
0.05% PEP005 Topical Gel (Day 1,8 application)

Treatment: drugs: PEP005
Vehicle Gel (Day 1,8 application)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the safety of PEP005 Topical Gel at 0.0025%, 0.01%, and 0.05% administered as two applications to patients with actinic keratosis (AKs) on the arms, shoulders, chest, face, and/or scalp</outcome>
      <timepoint>85 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the efficacy of PEP005 0.0025%, 0.01% and 0.05% Topical Gel in treating Actinic Keratoses</outcome>
      <timepoint>85 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female patients

          -  At least five individual AK lesions on the arms, shoulders, chest, face and/or scalp</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  A cosmetic or therapeutic procedure:

               -  within 10 cm of the selected AK lesions during the 3 months prior to study entry
                  or

               -  anywhere during the 4 weeks prior to study entry or anticipated treatment during
                  the study

          -  Treatment with 5-fluorouracil, imiquimod, diclofenac or photodynamic therapy:

               -  of lesions located within 10 cm of the selected AK lesions during the 3 months
                  prior to study entry or

               -  anywhere during the 4 weeks prior to study entry or anticipated treatment during
                  the study

          -  Use of acid-containing products, topical retinoids or light chemical peels within 10
             cm of the selected AK lesions during the 3 months prior to study entry, or anticipated
             treatment in this same area during the study

          -  Treatment with immuno-modulators, cytotoxic drugs, or interferon/interferon inducers
             during the 4 weeks prior to study entry or anticipated treatment during the study

          -  Treatment with psoralen plus UVA or use of UVB therapy during the 6 months prior to
             study entry or anticipated treatment during the study

          -  Use of systemic retinoids during the 6 months prior to study entry or anticipated
             treatment during the study

          -  Anticipated excessive or prolonged exposure to ultraviolet light or use of topical
             salves, creams or ointments to the selected AK lesions during the study

          -  Females of childbearing potential</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <hospital>Siller Medical - Brisbane</hospital>
    <hospital>Skin and Cancer Foundation - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Fremantle Dermatology - Fremantle</hospital>
    <hospital>Private Dermaology Clinic - Fremantle</hospital>
    <postcode>2050 - Sydney</postcode>
    <postcode>4000 - Brisbane</postcode>
    <postcode>3052 - Melbourne</postcode>
    <postcode>3168 - Melbourne</postcode>
    <postcode>6160 - Fremantle</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether topical application of PEP005 is safe for
      the treatment of actinic keratoses.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00107965</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Greg Siller</name>
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>